ライフサイエンスコーパス: non-small-cell lung cancer

1 ared to those with the less aggressive form (non-small cell lung cancer).

2 PD-L1) adnectin PET tracer, in patients with non-small cell lung cancer.

3 er, pancreatic cancer, colorectal cancer, or non-small cell lung cancer.

4 ominates the initial treatment of metastatic non-small cell lung cancer.

5 arly adenocarcinoma, a pathologic subtype of non-small cell lung cancer.

6 approximately 20% of patients with advanced non-small cell lung cancer.

7 s an unmet need in the clinical diagnosis of non-small cell lung cancer.

8 bined datasets of normal lung epithelium and non-small cell lung cancer.

9 activity in tumor tissues from patients with non-small cell lung cancer.

10 iferation and tumorigenicity of KEAP1-mutant non-small cell lung cancer.

11 th head and neck squamous cell carcinoma and non-small cell lung cancer.

12 ing that CNOT3 is required for the growth of non-small cell lung cancer.

13 ch include breast, prostate, colorectal, and non-small cell lung cancer.

14 in approximately 15% to 20% of patients with non-small cell lung cancer.

15 ized uptake value is a prognostic marker for non-small cell lung cancer.

16 verall survival for patients with metastatic non-small cell lung cancer.

17 study to explore and control for RNA-ITH in non-small cell lung cancer.

18 profiling study of 245 Chinese patients with non-small cell lung cancer.

19 gnosis of pulmonary nodules in patients with non-small cell lung cancer.

20 r (SqCLC), the second most common subtype of non-small cell lung cancer.

21 resent in approximately 30% of patients with non-small cell lung cancer.

22 g the evaluation of lung nodules and stage I non-small cell lung cancer.

23 with chemotherapy as first-line treatment of non-small-cell lung cancer.

24 y as a first-line treatment for ALK-positive non-small-cell lung cancer.

25 d death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer.

26 erapy, as first-line treatment of metastatic non-small-cell lung cancer.

27 hemotherapy-naive patients with non-squamous non-small-cell lung cancer.

28 ty, in patients with unresectable, stage III non-small-cell lung cancer.

29 unmet need for better therapies for squamous non-small-cell lung cancer.

30 alone as first-line therapy for non-squamous non-small-cell lung cancer.

31 next generation inhibitors targeting EGFR in non-small-cell lung cancer.

32 omarker-driven therapy questions in squamous non-small-cell lung cancer.

33 py for patients with metastatic non-squamous non-small-cell lung cancer.

34 on brain metastases from EGFR and ALK mutant non-small-cell lung cancer.

35 kinase inhibitor (TKI)-resistant EGFR-mutant non-small-cell lung cancers.

36 oantigens and the immune system in untreated non-small-cell lung cancers.

37 es, as it was shown for BRAF in melanoma and non-small-cell lung cancers.

38 nt or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were

39 6.9 months (IQR 22.3-31.5) for patients with non-small-cell lung cancer, 33.0 months (29.2-35.1) for

40 34 (31%) of 111 patients had non-small-cell lung cancer, 37 (33%) had melanoma, and 3

41 rinodular regions of nodules can distinguish non-small cell lung cancer adenocarcinomas from benign g

42 r-extracted imaging) features to distinguish non-small cell lung cancer adenocarcinomas from granulom

43 ytologically confirmed stage IV non-squamous non-small-cell lung cancer, an Eastern Cooperative Oncol

44 nt Committee on Cancer-defined stage IB-IIIA non-small-cell lung cancer, an Eastern Cooperative Oncol

45 amous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncol

46 as clinical therapy in malignancies such as non-small cell lung cancer and has shown good results in

47 the recent advances in precision therapy for non-small cell lung cancer and their implications on ima

48 survival in patients with previously treated non-small-cell lung cancer and also showed clinical bene

49 eractions and therapeutic vulnerabilities of non-small-cell lung cancer and assess the challenges and

50 tment of patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations.

51 ented expanding to all histological types of non-small-cell lung cancer and to add focus on immunothe

52 ee lines of previous therapy (for those with non-small-cell lung cancer and urothelial carcinoma) tha

53 five-class problem ranged between 0.64 (for non-small cell lung cancer) and 0.82 (for melanoma); all

54 riance of commonly observed mutated genes in non-small cell lung cancer, and their wild-type counterp

55 P2A (SMAPs) in Burkitt lymphoma, KRAS-driven non-small cell lung cancer, and triple-negative breast c

56 oesophageal junction adenocarcinoma, 27 with non-small-cell lung cancer, and 24 with urothelial carci

57 cogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers.

58 gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma.

59 e the progression of pre-invasive lesions in non-small cell lung cancer are poorly understood.

60 Using non-small cell lung cancer as a case study, we show that

61 alent in both adeno and squamous subtypes of non-small cell lung cancer, as well as additional tumor

62 diotherapy for nonoperative locally advanced non-small cell lung cancer between 2004 and 2014.

63 ard of care for many malignancies, including non-small cell lung cancer, but its benefits have not ex

64 and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be c

65 cle checkpoint kinase, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-media

66 ing glucose consumption and use it to screen non-small-cell lung cancer cell lines against bioactive

67 fic ligands that bind a CSC subpopulation of non-small cell lung cancer cells (defined by Aldefluor p

68 fective evolutionary games in co-cultures of non-small cell lung cancer cells that are sensitive and

69 We discovered that a subset of non-small cell lung cancer cells underwent a gradually p

70 CNOT3 suppresses proliferation of A549 human non-small cell lung cancer cells with enhanced mRNA stab

71 a novel mRNA degradation target of CNOT3 in non-small cell lung cancer cells.

72 ty to drive tumor invasion and metastasis of non-small cell lung cancer cells.

73 ells and of treatment with erlotinib of PC-9 non-small cell lung cancer cells.

74 the growth of K-Ras-addicted pancreatic and non-small cell lung cancer cells.

75 Transformed non-small-cell lung cancer cells, which maintain high gl

76 sing a 96-well automated workflow in a pilot non-small cell lung cancer classification study.

77 orthotopic immunocompetent murine models of non-small cell lung cancer: CMT167 (CMT) and Lewis lung

78 cohort, eight (30%; 13.8-50.2) of 27 in the non-small-cell lung cancer cohort, and three (13%, 2.7-3

79 l junction adenocarcinoma (cohorts A and B), non-small-cell lung cancer (cohort C), or urothelial car

80 conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras

81 In a genetically engineered mouse model of non-small cell lung cancer driven by K-Ras G12D and p53

82 this has not been validated in patients with non-small cell lung cancer due to the difficulty to obta

83 F-BMS-986192 in patients with advanced-stage non-small cell lung cancer eligible for nivolumab treatm

84 s were found in breast cancer, colon cancer, non-small cell lung cancer, esophageal adenocarcinoma, g

85 Two phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based

86 nd previously treated patients with advanced non-small-cell lung cancer expressing PD-L1.

87 uded in the basket dose-expansion cohort (12 non-small-cell lung cancer, five gynaecological malignan

88 a from (1) studies in patients with advanced non-small-cell lung cancer, FLAURA (osimertinib, n = 279

89 Adults with non-small cell lung cancer followed from 30 days post-di

90 nhibitors for oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by

91 logically documented stage III, unresectable non-small-cell lung cancer, for which they had received

92 mapped by deep learning in 100 patients with non-small cell lung cancer from the TRACERx cohort(6).

93 or older, had stage IV or recurrent squamous non-small-cell lung cancer, had previously been treated

94 inase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the m

95 ing of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-di

96 ly for the treatment of ROS1 fusion-positive non-small-cell lung cancers; histology-agnostic approval

97 lls from chemotherapy-naive individuals with non-small-cell lung cancer identified the transcription

98 ndings, elevated mRNA expression of CNOT3 in non-small cell lung cancer in comparison with the paired

99 measure mitochondrial membrane potential in non-small-cell lung cancer in vivo using a voltage-sensi

100 Systemic therapy for metastatic non-small cell lung cancer is selected according to the

101 idermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in

102 xamination of the AR RTK fusion landscape in non-small-cell lung cancer is lacking.

103 ase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic

104 he most frequently mutated version of RAS in non-small-cell lung cancer, KRAS(G12C), we have the oppo

105 dicts disease-free survival of patients with non-small cell lung cancer more accurately than clinical

106 inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.

107 (n = 4), and management of clinical stage I non-small cell lung cancer (n = 1) were developed and mo

108 econdary to melanoma (n = 29 with 75 BMs) or non-small cell lung cancer (n = 11 with 32 BMs) treated

109 ependent cohort of patients with early-stage non-small cell lung cancer (N = 14), where the therapeut

110 (n = 143), small cell lung cancer (n = 151), non-small cell lung cancer (n = 225), gastrointestinal c

111 atients with a confirmed diagnosis of either non-small-cell lung cancer (n=442) or small-cell lung ca

112 erapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC).

113 Cultured human non-small cell lung cancer (NSCLC) A549 cells take up th

114 Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enab

115 ocus exclusively on the role of NF-kappaB in non-small cell lung cancer (NSCLC) and discuss its contr

116 In non-small cell lung cancer (NSCLC) and prostate cancers,

117 2) whose silencing sensitized the human A549 non-small cell lung cancer (NSCLC) and SW620 colorectal

118 sults where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to perso

119 Tumors of human non-small cell lung cancer (NSCLC) are heterogeneous but

120 o the development of targeted therapies with non-small cell lung cancer (NSCLC) being a paradigm for

121 ceptor (EGFR) signaling is effective in some non-small cell lung cancer (NSCLC) but not in triple-neg

122 to the EGFR TKI osimertinib (AZD9291) in the non-small cell lung cancer (NSCLC) cell line H1975, whic

123 we applied this approach to a KRAS-dependent non-small cell lung cancer (NSCLC) cell line, H23-KRAS(G

124 A large panel of non-small cell lung cancer (NSCLC) cell lines (73 of 77)

125 s from central carbon metabolism, in over 80 non-small cell lung cancer (NSCLC) cell lines cultured u

126 toolkit we engineered phenotypically diverse non-small cell lung cancer (NSCLC) cells by conferring m

127 ived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enha

128 Validation data: One set of public non-small cell lung cancer (NSCLC) data.

129 ibution of platinum at the cellular level in non-small cell lung cancer (NSCLC) explant models after

130 eneration of NADPH; however, its function in non-small cell lung cancer (NSCLC) has not been establis

131 ty studies in patients with locally advanced non-small cell lung cancer (NSCLC) have been limited by

132 Non-small cell lung cancer (NSCLC) have been reported to

133 Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis

134 KRAS-mutant non-small cell lung cancer (NSCLC) is a major lung cance

135 A subset of non-small cell lung cancer (NSCLC) is driven by amplific

136 Non-small cell lung cancer (NSCLC) is known to have poor

137 the EGFR inhibitor (EGFRi), osimertinib, in non-small cell lung cancer (NSCLC) is limited by acquire

138 Non-small cell lung cancer (NSCLC) is often characterize

139 Non-small cell lung cancer (NSCLC) is the deadliest form

140 Non-small cell lung cancer (NSCLC) is the leading cause

141 Non-small cell lung cancer (NSCLC) is the most frequent

142 PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown.

143 y optimizing rheological parameters to print non-small cell lung cancer (NSCLC) patient derived xenog

144 This platform was also tested using non-small cell lung cancer (NSCLC) patient samples, wher

145 (2019-2021), the majority (63%) of stage III non-small cell lung cancer (NSCLC) patients are prescrib

146 Methods: Seventy-five non-small cell lung cancer (NSCLC) patients planned for

147 DG PET/CT radiomics signature in early-stage non-small cell lung cancer (NSCLC) patients treated with

148 This study examines a population of non-small cell lung cancer (NSCLC) patients with synchro

149 cells isolated from tumor tissue samples of non-small cell lung cancer (NSCLC) patients, and identif

150 espect to (18)F-FDG PET response criteria in non-small cell lung cancer (NSCLC) patients.

151 EGFR gene is commonly observed in tumors of non-small cell lung cancer (NSCLC) patients.

152 nological aspects in clinical specimens from non-small cell lung cancer (NSCLC) patients.

153 rns of local versus distant recurrences in a non-small cell lung cancer (NSCLC) population with mutat

154 and immunohistochemistry (IHC) on 8 pairs of non-small cell lung cancer (NSCLC) primary tumors and ma

155 oding RNA (lncRNA) that are involved in male non-small cell lung cancer (NSCLC) radiation sensitivity

156 at majority of miR-21-5p isolated from human non-small cell lung cancer (NSCLC) tissue possesses 3'-t

157 could potentiate the action of cisplatin in non-small cell lung cancer (NSCLC) treatment.

158 cribed RNA aptamer (trans-RA16) that targets non-small cell lung cancer (NSCLC) was previously identi

159 macrophages and monocytes from patients with non-small cell lung cancer (NSCLC) where c-MAF is overex

160 developed for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR-mutant tumo

161 Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoin

162 esses the growth of subcutaneously implanted non-small cell lung cancer (NSCLC) xenografts and nearly

163 In non-small cell lung cancer (NSCLC), accumulation of anti

164 tumor types, including subsets of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyro

165 ly prevalent in certain tumor types, notably non-small cell lung cancer (NSCLC), and associated with

166 ins have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level qu

167 radiotherapy is an option for patients with non-small cell lung cancer (NSCLC), distinguishing betwe

168 While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments

169 beta (ERbeta) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alter

170 chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resist

171 the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common hist

172 show that this vulnerability is conserved in non-small cell lung cancer (NSCLC), where SMARCA4 loss a

173 rt a critical role for proline catabolism in non-small cell lung cancer (NSCLC).

174 er cell integrity during clonal evolution in non-small cell lung cancer (NSCLC).

175 g the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC).

176 gly utilized to treat solid tumors including non-small cell lung cancer (NSCLC).

177 lower lobe is related with worse outcome of non-small cell lung cancer (NSCLC).

178 in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

179 death-1 blockers is a promising modality for non-small cell lung cancer (NSCLC).

180 poor survival particularly in patients with non-small cell lung cancer (NSCLC).

181 als for different types of cancer, including non-small cell lung cancer (NSCLC).

182 improve accuracy of pulmonary resection for non-small cell lung cancer (NSCLC).

183 t inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC).

184 FR) is a major player in the pathogenesis of non-small cell lung cancer (NSCLC).

185 inhibitors and immune checkpoint blockade in non-small cell lung cancer (NSCLC).

186 xicity anti-cancer agent imperialine against non-small cell lung cancer (NSCLC).

187 o assign effective personalized therapies in non-small cell lung cancer (NSCLC).

188 form has been applied to advanced metastatic non-small cell lung cancer (NSCLC).

189 for the response to these agents in treating non-small cell lung cancer (NSCLC).

190 utic approach for several cancers, including non-small cell lung cancer (NSCLC).

191 expression program of de novo lipogenesis in non-small cell lung cancer (NSCLC).

192 FR in treatment-naive patients with advanced non-small cell lung cancer (NSCLC).

193 ly silenced by promoter methylation in human non-small cell lung cancers (NSCLC) harboring mutations

194 cation, is elevated in both human and murine non-small cell lung cancers (NSCLC).

195 omplexes, occurs at very high frequencies in non-small cell lung cancers (NSCLC).

196 dermal growth factor receptor ( EGFR)-mutant non-small-cell lung cancer (NSCLC) and can mediate prima

197 r is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung c

198 Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk

199 The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against

200 of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-

201 in patients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or dela

202 The majority of non-small-cell lung cancer (NSCLC) cases are diagnosed a

203 ions and selected resynthesized compounds in non-small-cell lung cancer (NSCLC) cells showed that cyt

204 ere, using a proteomics-mediated approach in non-small-cell lung cancer (NSCLC) cells, we identified

205 t pool of ECT2 localizes to the nucleolus of non-small-cell lung cancer (NSCLC) cells, where it binds

206 -cell specific function in regulating CME in non-small-cell lung cancer (NSCLC) cells.

207 Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly be

208 e management of patients with advanced-stage non-small-cell lung cancer (NSCLC) in light of the ever-

209 first-line therapy for EGFR-mutant advanced non-small-cell lung cancer (NSCLC) is an epidermal growt

210 and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by precl

211 Non-small-cell lung cancer (NSCLC) is terminal in most p

212 genomic and transcriptomic heterogeneity in non-small-cell lung cancer (NSCLC) not only between tumo

213 se 2 trial of pembrolizumab in patients with non-small-cell lung cancer (NSCLC) or melanoma with untr

214 Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair de

215 EGFR-mutant non-small-cell lung cancer (NSCLC) patients inevitably d

216 on tomography (FDG-PET) response criteria in non-small-cell lung cancer (NSCLC) patients.

217 Non-small-cell lung cancer (NSCLC) represents approximat

218 new disease in patients with oligometastatic non-small-cell lung cancer (NSCLC) that did not progress

219 sociated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programm

220 proximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery w

221 systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver altera

222 head and neck squamous-cell cancer (HNSCC), non-small-cell lung cancer (NSCLC), and other solid tumo

223 an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic a

224 idermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC), failure of EGFR TKIs

225 of ensartinib in ALK-positive patients with non-small-cell lung cancer (NSCLC), in whom crizotinib t

226 noma of the head and neck (SCCHN), melanoma, non-small-cell lung cancer (NSCLC), or urothelial cancer

227 In non-small-cell lung cancer (NSCLC), the functions of OPN

228 or (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant e

229 ant regulator of acquired chemoresistance in non-small-cell lung cancer (NSCLC).

230 ogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC).

231 ce to oxidative stress in vitro and in human non-small-cell lung cancer (NSCLC).

232 has an important role in the development of non-small-cell lung cancer (NSCLC).

233 hed light on the role of the NF-kappaBeta in non-small-cell lung cancer (NSCLC).

234 maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC).

235 in patients with previously treated advanced non-small-cell lung cancer (NSCLC).

236 oracoscopic (VATS) lobectomy for early stage non-small-cell lung cancer (NSCLC).

237 first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC).

238 editing drive extensive heterogeneity within non-small-cell lung cancer (NSCLC).

239 ety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC).

240 hen compared to open lobectomy for cT1-2N1M0 non-small-cell lung cancer (NSCLC).

241 oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC).

242 ined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC).

243 compounds that inhibit the proliferation of non-small-cell lung cancer (NSCLC).

244 ajor obstacle to the successful treatment of non-small-cell lung cancer (NSCLC).

245 mal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC).

246 ia were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung canc

247 Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase i

248 R (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformat

249 specific mutations characteristic of nearby non-small cell lung cancers (NSCLCs).

250 exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)(1).

251 ated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward

252 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.

253 gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma.

254 with poor clinical outcome in patients with non-small cell lung cancer, particularly those with lung

255 The Cancer Genome Atlas (TCGA) datasets for non-small cell lung cancer patients also suggest an effe

256 of ATR is a promising therapy for the 10% of non-small cell lung cancer patients harboring mutations

257 Methods: Seventy-five non-small cell lung cancer patients planned for lobectom

258 FDG PET/CT radiomic signature in early-stage non-small cell lung cancer patients treated with stereot

259 f 100 clear-cell renal cell carcinoma and 99 non-small-cell lung cancer patients and identify both co

260 ll RNA sequencing (scRNA-seq) to map TIMs in non-small-cell lung cancer patients.

261 ed to directly detect hsa-miR-21-5p in eight non-small cell lung cancer plasma samples.

262 Approximately 25% of all patients with non-small-cell lung cancer present with resectable stage

263 Non-small cell lung cancer remains a highly lethal malig

264 Non-small cell lung cancer remains the leading cause of

265 ial with the antifibrotic drug nintedanib in non-small cell lung cancer reported clinical benefits in

266 h factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in

267 II clinical testing in ERBB2 exon 20-mutant non-small cell lung cancer resulted in a confirmed objec

268 cted from real PET/CT scans of patients with non-small cell lung cancer served as model for three 3-d

269 Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular test

270 selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple route

271 g anti-PD-1-treated patients with metastatic non-small cell lung cancer, those with lower PD-1/PD-L1

272 se, objective responses were 12 (43%) of 28 (non-small-cell lung cancer), three (10%) of 31 (melanoma

273 tion of CNOT3 facilitates the development of non-small cell lung cancer through down-regulation of Kr

274 racterized as combinational drug targets for non-small cell lung cancer treatments.

275 a and myocardial infarction in patients with non-small-cell lung cancer (two [7%] of 27 patients), an

276 sociated with local control in patients with non-small cell lung cancer undergoing SBRT and could be

277 we analysed the prognostic value of SASH1 in non-small cell lung cancers using publicly available dat

278 e 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and his

279 l survival rate for patients with metastatic non-small cell lung cancer was less than 5%.

280 f immune checkpoint inhibitors in metastatic non-small-cell lung cancer, we designed a trial to test

281 ingle-cell RNA sequencing in human and mouse non-small-cell lung cancers, we identify a cluster of de

282 stro-oesophageal junction adenocarcinoma and non-small-cell lung cancer were also enrolled (in two ad

283 lorectal cancer were excluded; patients with non-small-cell lung cancer were later excluded in an ame

284 Patients with chemotherapy-naive metastatic non-small-cell lung cancer were randomly assigned (1:1:1

285 s, aged 18 years or older, with ALK-positive non-small-cell lung cancer were randomly assigned (2:1)

286 comparative study of patients with advanced non-small cell lung cancer who received CPIs combined wi

287 tatic, MET-amplified, EGFR mutation-positive non-small-cell lung cancer, who had progressed on EGFR T

288 er of regulatory sites within the genomes of non-small cell lung cancers with a global scan for open

289 b as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alectinib twic

290 rvival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligan

291 patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at ba

292 potential neoadjuvant regimen for resectable non-small-cell lung cancer, with a high proportion of pa

293 urs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence rep

294 sly untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mu

295 ibitors (ICIs) hold promise in patients with non-small-cell lung cancer without druggable mutations a

296 ologically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or A

297 patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or A

298 Using (18)F-flortanidazole PET imaging in a non-small cell lung cancer xenograft model, we showed th

299 effect of acute metformin administration on non-small cell lung cancer xenograft tumor hypoxia using

300 ring a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft.